PureTech Health (LON:PRTC) Shares Down 12.4% – Here’s Why

PureTech Health plc (LON:PRTC) dropped 12.4% during trading on Thursday . The stock traded as low as GBX 100.40 ($1.28) and last traded at GBX 103 ($1.32). Approximately 3,018,245 shares traded hands during mid-day trading, an increase of 192% from the average daily volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.50).

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group restated a “buy” rating and issued a GBX 455 ($5.81) target price on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Trading Up 7.0 %

The firm has a 50 day simple moving average of GBX 136.77 and a 200 day simple moving average of GBX 148.52. The firm has a market cap of £331.02 million, a P/E ratio of -4.52 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.